Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 34

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 34
---
 total liabilities. Therefore, if you purchase shares of
our common stock you may experience immediate and substantial dilution. See the section titled “Dilution” of this prospectus
supplement for a more detailed discussion of the dilution you may incur if you purchase common stock in this offering.

It is not possible to predict the aggregate proceeds resulting from sales made under the Sales Agreement.

Subject to certain limitations in the Sales Agreement and compliance
with applicable law, we have the discretion to deliver an issuance notice to the Agent at any time throughout the term of the Sales Agreement.
The number of shares that are sold through the Agent after delivering an issuance notice, if any, will fluctuate based on a number of
factors, including the market price of shares of our common stock during the sales period, the limits we set with the Agent in any applicable
issuance notice and the demand for shares of our common stock during the sales period. Because the price per share of each share of common
stock sold pursuant to the Sales Agreement will fluctuate during this offering, it is not currently possible to predict the number of
shares of common stock that will be sold or the aggregate proceeds we will raise in connection with those sales under the Sales Agreement,
and we may not sell any shares of common stock under the Sales Agreement.

Future sales of our common stock, or the perception that such future sales may occur, may cause our stock price to decline.

Sales of a substantial number
of shares of our common stock in the public market, or the perception that these sales could occur, following this offering could cause
the market price of our common stock to decline. A substantial majority of the outstanding shares of our common stock are, and the shares
of common stock sold in this offering upon issuance will be, freely tradable without restriction or further registration under the Securities
Act.

We may not be able to maintain the listing of our common stock on Nasdaq, which could adversely affect our liquidity and the trading volume and market price of our common stock and decrease or eliminate your investment.

Our common stock is listed
on The Nasdaq Capital Market. If we violate the maintenance requirements for continued listing of our common stock, our common stock may
be delisted. In the past, we have received letters from Nasdaq notifying us that we were not in compliance with the $1.00 minimum bid
price requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Although we